Cardiff Oncology (CRDF) Expected to Announce Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) is anticipated to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $0.09 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Cardiff Oncology Stock Down 4.0 %

CRDF stock opened at $4.56 on Tuesday. The business has a 50 day moving average price of $4.09 and a 200 day moving average price of $3.19. The stock has a market cap of $233.17 million, a price-to-earnings ratio of -4.85 and a beta of 1.77. Cardiff Oncology has a fifty-two week low of $1.66 and a fifty-two week high of $6.42.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CRDF shares. HC Wainwright dropped their price objective on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Piper Sandler upped their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday, December 13th.

Insider Activity

In other Cardiff Oncology news, Director Gary W. Pace acquired 350,115 shares of the stock in a transaction on Wednesday, December 11th. The stock was purchased at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the purchase, the director now directly owns 1,047,876 shares in the company, valued at $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 7.60% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.